While the number of Biobanks worldwide is growing rapidly, quality control of the whole process Is a requirement to ensure the value of the biobanks. Standardization is needed to allow researchers to integrate results obtained of specimen tests from 1 or more biobanks. Standardization also includes the QC Process, which needs to cover all aspects of pre-analytics and sample storage. In addition validation of specimen/donor metaparameters is of additional value.

NMR is especially suited to perform QC-analysis of liquid biopsies and can deliver a large number of criteria based on one QC measurement per sample. In addition to QC Information NMR can deliver a large number of metabolic information using the same spectra generated during the QC process. With this information in urine 150 metabolites in 2 age ranges are quantified. In plasma/serum 115 lipoprotein related parameters (including subclasses) and 26 metabolites/parameters are analyzed and quantified, the whole process is under push button automation and can be handled by a trained medical technical assistant.

In addition to quality control, biobanks can now support epidemiological studies or clinical trials by using the metadata of selected NMR spectra or quantification results. This will reduce the need for new aliquots and substantially reducing the cost of clinical trials or research studies.

Further savings can be gained by sharing the spectral data. New NMR-based diagnostic tests can be validated on a worldwide basis and on multiple phenotypes without exploding the cost of the trial. Data generated from an 11 IVDr platform Inter-Laboratory Trial proves this unique benefit of NMR1.

Director Clinical Key Account Management at Bruker Biospin

Dipl.-Ing Roland Leiminger was born in 1961 and studied at the University of Applied Sciences, Reutlingen and Berlin. His focus is on instrumental analytics, biotechnology and reactor design. He is Director Clinical Key Account Management at Bruker Biospin. He is responsible for the distribution of NMR systems and the implementation of new application strategies. Its territorial responsibility extends in the EIMEA area. His main topics are biobanks, research collaborations and the opening of new diagnostic work areas by NMR with SOP processing. He has more than 30 years of experience in environmental and medical diagnostics. He has successfully introduced new technologies in the various technological markets. His successes have always been characterized by excellent market knowledge, future-oriented and creative and solution-oriented acting. He is a team player with clear visions.

The technological revolution in life science research in the last decade has been nothing short of phenomenal. Exotic new technologies, particularly focused on elucidating the properties and behavior of the regulation and the products of nucleic acid based biological agents, have exponentially accelerated progress in the corresponding investigative ‘-omic’ domains e.g. Genomics, Proteomics, Transcriptomics, Metabolomics, etc. The speed and sophistication of developing treatments for our new shared human experience of the tragic worldwide pandemic have made phrases like ‘medical miracle’ common lexicon and has given literally every human on Earth a quick lesson in biotechnology.

This revolution has created a less obvious but increasingly critical bottleneck. Aside from the advances in computational or virtual modeling, most data is still generated from analyzing a starting material or substrate. These recent technological advances heavily favor biological materials. This will often start with the raw materials extracted from living entities and then progress to the processed constituents of those materials e.g. nucleic acids and proteins. The accumulation and corresponding management (physical and data based) of all these materials sometimes gets pushed down the priority list as the resources are understandably focused on the end result.

Two basic pressure points resulted from this biological material shift: sheer quantities growing faster than can be managed and, most critically, requirement for ultra-low temperature storage. These two factors are captured in a simple anecdotal example of this challenge: migration from manual freezers to automated sample storage in order to alleviate this critical bottleneck.

In this short workshop, we will explore the current status of this challenge and provide some insight into the solutions that will help with justification of the most significant impediment most investigators face: budgeting.

Business Development- Biobanking for North America and Asia Pacific, Liconic Instruments

Mr. Broach has supported Life Science technology development for 20+ years, across many disciplines, including sample management automation, cell culture, protein crystallography, optical readout technology, and combinatorial chemistry. He has held product management and product commercialization roles for some of the first large scale automated biosample management technologies to reach the market, beginning in 2008.

Mr. Broach has degrees in Molecular Biology and Robotics.
He currently serves as Business Development Director – Biobanking for Liconic Instruments in North America and the Asia Pacific region

For over 70 years, Becton Dickinson (BD) has been one of the leading providers of solutions designed to improve the quality of in vitro diagnostic testing. Our innovative solutions and services help to provide greater safety, accuracy, and reliability.

Join us for a 10-minute session where Rama Nassani, our Clinical Specialist from BD will shed light on the following preanalytical solutions:

• An innovation in the Chemistry space which helps in improving patient outcomes through a BD patented blood collection tube technology – BD Barricor™ o Improving turnaround time
  o Collecting lesser blood from patients by consolidating tests in a single tube
  o Replacing gel with a mechanical separator
• A cutting-edge technology which helps in improving patient experience – BD UltraTouch™
  o Reducing patient pain
  o Improving turnaround time
  o Potentially delivering better Sepsis management outcomes

Clinical Specialist – MENA, BD Life Sciences – Integrated Diagnostic Solutions

Rama has a graduation degree in medical laboratory science with a clinical background and is MLS (ASCP)CM certified from the American Society for Clinical Pathology. Her role in BD involves delivering lectures in MENA region on topics related to the importance of the preanalytical stage. She has also conducted 15+ quality assurance programs across the MENA region and trained 1000+ healthcare professionals.